# Capacity Bio

**Canonical:** https://apis.io/providers/capacity-bio/  
**Website:** https://capacitybio.com/  
**APIs profiled:** 0

Capacity Bio is a clinical-stage biotechnology company developing mitophagy therapeutics to restore mitochondrial quality control in age- and disease-related conditions. Its platform advances small molecules, peptides, and nanoparticles that enhance identification and clearance of dysfunctional mitochondria. With operations in Los Angeles and Tokyo, the company closed a $35M financing round in 2023 and is backed by Insight Partners. As a drug-development firm, Capacity Bio publishes no public API, developer platform, or SDK surface; this profile is maintained in the API Evangelist network as a company record.

## Kin Score — 5.0 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 5.0).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Tags

Company, Biotech Therapeutics, Mitophagy, Mitochondrial Biology, Drug Development, Therapeutics, Biotechnology

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/capacity-bio/). Scores are computed from the provider's own public artifacts under a published rubric.